Syndax Pharmaceuticals, Inc. Operating Cash Flow
Syndax Pharmaceuticals, Inc. (SNDX) reported Operating Cash Flow of -$80.62 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-04
- Syndax Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$30.27M.
- Syndax Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$50.34M.
- Syndax Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$69.49M.
- Syndax Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$70.53M.
- Syndax Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$322.98M.
- Syndax Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$274.90M.
- Syndax Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$160.60M.
- Syndax Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$133.68M, a 558.88% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$30.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$80.62M 10-Q · filed 2026-08-04 | -$150.10M derived: sum of 3 quarters · filed 2026-08-04 | -$220.64M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$50.34M 10-Q · filed 2026-04-30 | -$119.83M derived: sum of 2 quarters · filed 2026-04-30 | -$190.37M derived: sum of 3 quarters · filed 2026-04-30 | -$278.16M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$69.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$140.02M derived: sum of 2 quarters · filed 2026-02-26 | -$227.82M derived: sum of 3 quarters · filed 2026-08-04 | -$322.98M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$70.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$158.33M derived: sum of 2 quarters · filed 2026-08-04 | -$253.49M 10-Q · filed 2025-11-03 | -$310.88M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$87.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$182.96M 10-Q · filed 2026-08-04 | -$240.34M derived: sum of 3 quarters · filed 2026-08-04 | -$302.67M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$95.16M 10-Q · filed 2026-04-30 | -$152.55M derived: sum of 2 quarters · filed 2026-04-30 | -$214.87M derived: sum of 3 quarters · filed 2026-04-30 | -$286.52M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | -$57.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$119.71M derived: sum of 2 quarters · filed 2026-02-26 | -$191.35M derived: sum of 3 quarters · filed 2026-02-26 | -$274.90M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$62.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$133.97M derived: sum of 2 quarters · filed 2025-11-03 | -$217.51M 10-Q · filed 2025-11-03 | -$258.86M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$71.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | -$155.19M 10-Q · filed 2025-08-04 | -$196.54M derived: sum of 3 quarters · filed 2026-02-26 | -$241.19M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$83.55M 10-Q · filed 2025-05-05 | -$124.90M derived: sum of 2 quarters · filed 2026-02-26 | -$169.55M derived: sum of 3 quarters · filed 2026-02-26 | -$204.92M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$41.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$86.00M derived: sum of 2 quarters · filed 2026-02-26 | -$121.37M derived: sum of 3 quarters · filed 2026-02-26 | -$160.60M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$44.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$80.02M derived: sum of 2 quarters · filed 2024-11-05 | -$119.25M 10-Q · filed 2024-11-05 | -$142.15M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$35.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$74.60M 10-Q · filed 2024-08-01 | -$97.49M derived: sum of 3 quarters · filed 2025-03-03 | -$126.04M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$39.23M 10-Q · filed 2024-05-08 | -$62.12M derived: sum of 2 quarters · filed 2025-03-03 | -$90.67M derived: sum of 3 quarters · filed 2025-03-03 | -$130.97M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$22.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$51.44M derived: sum of 2 quarters · filed 2025-03-03 | -$91.74M derived: sum of 3 quarters · filed 2025-03-03 | -$133.68M 10-K · filed 2025-03-03 |
| 2022-09-30 | -$28.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$68.85M derived: sum of 2 quarters · filed 2023-11-02 | -$110.78M 10-Q · filed 2023-11-02 | -$10.07M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$40.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$82.24M 10-Q · filed 2023-08-03 | $18.47M derived: sum of 3 quarters · filed 2024-02-27 | -$6.47M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$41.93M 10-Q · filed 2023-05-08 | $58.78M derived: sum of 2 quarters · filed 2024-02-27 | $33.83M derived: sum of 3 quarters · filed 2024-02-27 | $9.79M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $100.71M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $75.77M derived: sum of 2 quarters · filed 2024-02-27 | $51.72M derived: sum of 3 quarters · filed 2024-02-27 | $29.13M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$24.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$48.99M derived: sum of 2 quarters · filed 2022-11-03 | -$71.58M 10-Q · filed 2022-11-03 | -$87.21M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$24.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$46.63M 10-Q · filed 2022-08-08 | -$62.27M derived: sum of 3 quarters · filed 2023-02-28 | -$80.56M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$22.59M 10-Q · filed 2022-05-09 | -$38.22M derived: sum of 2 quarters · filed 2023-02-28 | -$56.52M derived: sum of 3 quarters · filed 2023-02-28 | -$77.92M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$15.63M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$33.93M derived: sum of 2 quarters · filed 2023-02-28 | -$55.34M derived: sum of 3 quarters · filed 2023-02-28 | -$71.26M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$18.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$39.70M derived: sum of 2 quarters · filed 2021-11-15 | -$55.63M 10-Q · filed 2021-11-15 | -$68.36M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$21.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$37.33M 10-Q · filed 2021-08-09 | -$50.06M derived: sum of 3 quarters · filed 2022-03-01 | -$58.59M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$15.93M 10-Q · filed 2021-05-11 | -$28.65M derived: sum of 2 quarters · filed 2022-03-01 | -$37.18M derived: sum of 3 quarters · filed 2022-03-01 | -$49.71M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$12.73M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$21.26M derived: sum of 2 quarters · filed 2022-03-01 | -$33.78M derived: sum of 3 quarters · filed 2022-03-01 | -$50.61M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$8.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$21.05M derived: sum of 2 quarters · filed 2020-11-05 | -$37.88M 10-Q · filed 2020-11-05 | -$52.93M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-06-30 | -$12.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$29.36M 10-Q · filed 2020-08-06 | -$44.40M derived: sum of 3 quarters · filed 2021-03-12 | -$62.87M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-03-31 | -$16.83M 10-Q · filed 2020-05-07 | -$31.87M derived: sum of 2 quarters · filed 2021-03-12 | -$50.34M derived: sum of 3 quarters · filed 2021-03-12 | -$65.49M derived: sum of 4 quarters · filed 2021-03-12 |
| 2018-12-31 | -$15.04M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | -$33.51M derived: sum of 2 quarters · filed 2021-03-12 | -$48.66M derived: sum of 3 quarters · filed 2021-03-12 | -$68.53M 10-K · filed 2021-03-12 |
| 2018-09-30 | -$18.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$33.62M derived: sum of 2 quarters · filed 2019-11-07 | -$53.49M 10-Q · filed 2019-11-07 | -$66.21M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-06-30 | -$15.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$35.02M 10-Q · filed 2019-08-07 | -$47.74M derived: sum of 3 quarters · filed 2020-03-05 | -$57.92M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-03-31 | -$19.87M 10-Q · filed 2019-05-08 | -$32.59M derived: sum of 2 quarters · filed 2020-03-05 | -$42.77M derived: sum of 3 quarters · filed 2020-03-05 | |
| 2017-12-31 | -$12.72M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | -$22.90M derived: sum of 2 quarters · filed 2020-03-05 | -$47.37M 10-K · filed 2020-03-05 | |
| 2017-09-30 | -$10.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | -$34.65M 10-Q · filed 2018-11-05 | ||
| 2017-06-30 | -$24.47M 10-Q · filed 2018-08-08 | |||
| 2016-12-31 | -$35.16M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |